ReviewNPJ vaccines2023
Outlook of pandemic preparedness in a post-COVID-19 world.
Review in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 5 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- COVID-19 Pandemic: A Comprehensive Meta-Review of Global Impacts, Responses, and Future Preparedness.The clinical respiratory journal · 2025Pooled it
- The efficacy and effectiveness of COVID-19 vaccines in Iran: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Systemic cytokines drive conserved severity-associated myeloid responses across bacterial and viral infections.Communications biology · 2025Pooled it
- Epidemic and Pandemic Preparedness and Response in a Multi-Hazard Context: COVID-19 Pandemic as a Point of Reference.International journal of environmental research and public health · 2024Pooled it
- Influence of government policies on handwashing and vaccine uptake in Kenya, Uganda, and Tanzania to prevent and control COVID-19: a systematic review.Frontiers in public health · 2024Pooled it
- Intersectional inequalities in COVID-19 hospitalisation and mortality: A nationwide MAIHDA study of Swedish adults across four pandemic waves (2020-2022).SSM - population health · 2026Article
- Vaccine acceptance in a future pandemic after COVID-19 and its decision drivers in Japan.NPJ vaccines · 2026Article
- Nanoparticles for antiviral nucleotide analogs: approaches and analytical challenges.Journal of virology · 2026Review
- Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses.Antimicrobial agents and chemotherapy · 2026Article
- Coronavirus M Protein Hijacks Toll-Interacting Protein (TOLLIP) to Suppress NF-κB Signaling and Promote Immune Evasion.MedComm · 2026Article
- Hantavirus Emergence in a Changing World: Virology, Pathogenesis, Surveillance, and One Health Preparedness.Microorganisms · 2026Review
- Analysing outbreak signals, 2013-2024: The amsterdam UMC centre for Tropical Medicine and Travel Medicine Epi Alert programme - an observational study.New microbes and new infections · 2026Article
- Longitudinal study of the immunological response to the SARS-CoV-2 vaccine in Instituto Português de Oncologia of Coimbra professionals.IJID regions · 2026Article
- Enhancing respiratory virus surveillance among hospitalised children: a machine learning-based predictive model.BMJ paediatrics open · 2026Article
- Adolescents' perceptions of media messages and their preventive health behaviors: a longitudinal study.Pediatric research · 2026Article
- Research priorities for improved pandemic and epidemic intelligence.The Lancet. Global health · 2026Review
- Financing Regimes and Case-Mix Complexity in Psychiatric Hospitals Beyond the Pandemic Shock-Insights from a Regional European Healthcare System.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Optimizing antimicrobial stewardship during operational upheaval: lessons in resiliency from the COVID-19 pandemic.Infection control and hospital epidemiology · 2026Article
- The 100 Days Mission: a perspective on accelerating vaccine manufacturing for future pandemics.BMC global and public health · 2026Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic was met with rapid, unprecedented global collaboration and action. Even still, the public health, societal, and economic impact may be felt for years to come. The risk of another pandemic occurring in the next few decades is ever-present and potentially increasing due to trends such as urbanization and climate change. While it is difficult to predict the next pandemic pathogen threat, making reasonable assumptions today and evaluating prior efforts to plan for and respond to disease outbreaks and pandemics may enable a more proactive, effective response in the future. Lessons from the COVID-19 response and pandemic influenza preparedness underscore the importance of strengthening surveillance systems, investing in early-stage research on pandemic pathogens and development of platform technologies, and diversifying response plans across a range of tactics to enable earlier access to safe and effective interventions in the next pandemic. Further, sustaining the robust vaccine manufacturing capacity built because of COVID-19 will keep it ready for rapid response in the future. These actions will not be successful without improved global coordination and collaboration. Everyone, including the biopharmaceutical industry, has a role to play in pandemic preparedness, and working together will ensure that the most lives are saved in the next pandemic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.